Atyr Pharma Stock Analysis
| ATYR Stock | 0.96 0.00 0.000002% |
IPO Date 7th of May 2015 | 200 Day MA 2.8633 | 50 Day MA 0.742 | Beta 0.576 |
At this time, ATyr Pharma's Net Debt is relatively stable compared to the past year. As of 02/04/2026, Debt To Equity is likely to grow to 0.18, while Short Term Debt is likely to drop slightly above 1.1 M. ATyr Pharma's financial risk is the risk to ATyr Pharma stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.16 | Current Value 0.23 | Quarterly Volatility 0.20464601 |
aTyr Pharma is overvalued with Real Value of 0.74 and Target Price of 4.36. The main objective of ATyr Pharma stock analysis is to determine its intrinsic value, which is an estimate of what aTyr Pharma is worth, separate from its market price. There are two main types of ATyr Pharma's stock analysis: fundamental analysis and technical analysis.
The ATyr Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ATyr Pharma is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. ATyr Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. ATyr Stock Analysis Notes
About 60.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.07. Some equities with similar Price to Book (P/B) outperform the market in the long run. aTyr Pharma recorded a loss per share of 0.83. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 1st of July 2019. For more info on aTyr Pharma please contact MS MD at 858 731 8389 or go to https://atyrpharma.com.aTyr Pharma Investment Alerts
| aTyr Pharma is way too risky over 90 days horizon | |
| aTyr Pharma has some characteristics of a very speculative penny stock | |
| aTyr Pharma appears to be risky and price may revert if volatility continues | |
| aTyr Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 235 K. Net Loss for the year was (64.02 M) with loss before overhead, payroll, taxes, and interest of (61.37 M). | |
| ATyr Pharma generates negative cash flow from operations | |
| About 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis |
ATyr Largest EPS Surprises
Earnings surprises can significantly impact ATyr Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-04-30 | 2025-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2025-08-07 | 2025-06-30 | -0.1845 | -0.22 | -0.0355 | 19 | ||
2025-03-12 | 2024-12-31 | -0.226 | -0.1809 | 0.0451 | 19 |
ATyr Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 95.07 M.ATyr Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.62) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | (1.05) | (1.00) |
Management Efficiency
aTyr Pharma has return on total asset (ROA) of (0.4959) % which means that it has lost $0.4959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0349) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma's management efficiency ratios could be used to measure how well ATyr Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/04/2026, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, ATyr Pharma's Non Currrent Assets Other are relatively stable compared to the past year. As of 02/04/2026, Other Current Assets is likely to grow to about 9.8 M, while Non Current Assets Total are likely to drop slightly above 9.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.85 | 0.89 | |
| Tangible Book Value Per Share | 0.85 | 0.89 | |
| Enterprise Value Over EBITDA | (4.70) | (4.46) | |
| Price Book Value Ratio | 3.46 | 3.63 | |
| Enterprise Value Multiple | (4.70) | (4.46) | |
| Price Fair Value | 3.46 | 3.63 | |
| Enterprise Value | 243.9 M | 256.1 M |
The strategic vision of aTyr Pharma management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Technical Drivers
As of the 4th of February, ATyr Pharma shows the Downside Deviation of 4.34, semi deviation of 3.77, and Risk Adjusted Performance of 0.0259. aTyr Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm aTyr Pharma jensen alpha and semi variance to decide if aTyr Pharma is priced correctly, providing market reflects its regular price of 0.95999998 per share. Given that ATyr Pharma is a hitting penny stock territory we recommend to closely look at its total risk alpha.aTyr Pharma Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ATyr Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for aTyr Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
aTyr Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ATyr Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ATyr Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ATyr Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denyes Nancy over three weeks ago Acquisition by Denyes Nancy of 412500 shares of ATyr Pharma at 0.7127 subject to Rule 16b-3 | ||
Coughlin Timothy over six months ago Acquisition by Coughlin Timothy of 50000 shares of ATyr Pharma, at 3.34 subject to Rule 16b-3 | ||
Denyes Nancy over six months ago Disposition of 899 shares by Denyes Nancy of ATyr Pharma, at 3.78 subject to Rule 16b-3 | ||
Denyes Nancy over a year ago Acquisition by Denyes Nancy of 275000 shares of ATyr Pharma, at 3.74 subject to Rule 16b-3 | ||
Schimmel Paul over a year ago Acquisition by Schimmel Paul of 52300 shares of ATyr Pharma, at 1.9319 subject to Rule 16b-3 |
ATyr Pharma Outstanding Bonds
ATyr Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. aTyr Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ATyr bonds can be classified according to their maturity, which is the date when aTyr Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| APTV 415 01 MAY 52 Corp BondUS00217GAC78 | View | |
| APTV 325 01 MAR 32 Corp BondUS00217GAB95 | View | |
| ASBBNK 1625 22 OCT 26 Corp BondUS00216LAD55 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
ATyr Pharma Predictive Daily Indicators
ATyr Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ATyr Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ATyr Pharma Forecast Models
ATyr Pharma's time-series forecasting models are one of many ATyr Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ATyr Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.ATyr Pharma Total Assets Over Time
ATyr Pharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which ATyr Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.ATyr Pharma Debt Ratio | 23.0 |
ATyr Pharma Corporate Bonds Issued
ATyr Short Long Term Debt Total
Short Long Term Debt Total |
|
About ATyr Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ATyr Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ATyr shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ATyr Pharma. By using and applying ATyr Stock analysis, traders can create a robust methodology for identifying ATyr entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (313.30) | (297.63) | |
| Operating Profit Margin | (332.35) | (315.73) | |
| Net Loss | (313.30) | (297.64) | |
| Gross Profit Margin | 0.75 | 0.79 |
Current ATyr Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ATyr analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ATyr analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 4.36 | Strong Buy | 11 | Odds |
Most ATyr analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ATyr stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of aTyr Pharma, talking to its executives and customers, or listening to ATyr conference calls.
ATyr Stock Analysis Indicators
aTyr Pharma stock analysis indicators help investors evaluate how ATyr Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ATyr Pharma shares will generate the highest return on investment. By understating and applying ATyr Pharma stock analysis, traders can identify ATyr Pharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 26 M | |
| Total Stockholder Equity | 70 M | |
| Net Borrowings | -497 K | |
| Capital Lease Obligations | 13.3 M | |
| Property Plant And Equipment Net | 11.9 M | |
| Cash And Short Term Investments | 72.1 M | |
| Net Invested Capital | 70 M | |
| Cash | 11.1 M | |
| 50 Day M A | 0.742 | |
| Total Current Liabilities | 15 M | |
| Investments | 17.2 M | |
| Stock Based Compensation | 3 M | |
| Common Stock Shares Outstanding | 74.3 M | |
| Total Cashflows From Investing Activities | 17.2 M | |
| Free Cash Flow | -69.2 M | |
| Other Current Assets | 8.1 M | |
| Accounts Payable | 4.3 M | |
| Net Debt | 2.2 M | |
| Other Operating Expenses | 68.1 M | |
| Non Current Assets Total | 14.9 M | |
| Liabilities And Stockholders Equity | 96.8 M | |
| Non Currrent Assets Other | 3 M |
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.